3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Interventional
1
Sponsor
Conditions
Neoplasms
19
Breast Neoplasms
15
Prostatic Neoplasms
14
Colorectal Neoplasms
14
Hematopoietic and Lymphatic System Neoplasm
13
Lung Neoplasms
11
Ovarian Neoplasms
5
Multiple Myeloma
5
Hematologic Neoplasms
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Malignant Solid Neoplasm
4
Hematopoietic and Lymphoid System Neoplasm
4
Depression
4
Uterine Cervical Neoplasms
3
Neoplasm Metastasis
3
Lymphoma
3
Laryngeal Neoplasms
3
Head and Neck Neoplasms
3
Anxiety Disorders
3
Anatomic Stage I Breast Cancer AJCC v8
3
Advanced Malignant Solid Neoplasm
3
Urinary Bladder Neoplasms
2
Triple Negative Breast Neoplasms
2
Thyroid Cancer, Papillary
2
Oropharyngeal Neoplasms
2
Mouth Neoplasms
2
Motor Activity
2
Melanoma
2
Malignant Female Reproductive System Neoplasm
2
Leukemia, Myeloid, Acute
2
Interventions
Cyclophosphamide
20
Brentuximab Vedotin
20
fludarabine
16
Lenalidomide
13
Rituximab
12
Dexamethasone
12
fludarabine phosphate
10
Melphalan
10
Busulfan
10
Mycophenolic Acid
9
dacetuzumab
7
Whole-Body Irradiation
7
Tacrolimus
7
pirtobrutinib
6
Doxorubicin
6
Bortezomib
6
Azacitidine
6
ruxolitinib
5
Vincristine
5
Prednisone
5
Imatinib Mesylate
5
ponatinib
4
pomalidomide
4
Mesna
4
Granulocyte Colony-Stimulating Factor
4
Etoposide
4
Bone Marrow Transplantation
4
Bendamustine Hydrochloride
4
venetoclax
3
nilotinib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Hematologic Diseases
×
Interviews as Topic
×
Clear all
NCT03272789
2019-01-23
REBOND
Institut Paoli-Calmettes
Phase NA
Unknown
32 enrolled